“This year, we will launch a first-of-its-kind robotics platform for urology with Monarch.”

In context

“icularly well, delivering operational growth of approximately 1823% in the quarter. We remain the market leader in electrophysiology, and we plan to expand our position in pulse field ablation. BariPulse has now been used to treat nearly forty thousand atrial fibrillation patients globally, and we look forward to submitting our dual energy thermo cool SMARTouch SF catheter for use in the US market in 2026. We are also seeing positive data for our Omnipulse catheter, which has the potential to further redefine post-field ablation. In fact, we anticipate launching a new catheter every year through the end of the decade as we build an industry-leading portfolio in PFA complemented by at least two Carto updates each year. In surgery, we are reinventing procedures through robotics and digital. This year, we will launch a first-of-its-kind robotics platform for urology with Monarch. Technology was first to market in bronchoscopy, helping diagnose and treat lung cancer. And this year, we'll create another first with Monarch, becoming the only robotic endoluminal and percutaneous platform for the treatment of kidney stones and other renal conditions. We also recently announced the FDA de novo submission of our Optava robotic surgery system. And with continued innovation in surgical instrumentation, including our recent launch of the Ethicon 4,000 stapler, we anticipate continued growth as we reduce complications and elevate the surgical experience across specialties. And finally, vision, which delivered robust annual operational sales growth of 5.3% with particularly strong momentum in surgical vision. In 2025, we launched IQVIA OASIS MAX disposable lenses for astigmat”